ERBB2 and neoplasm: Surface-engineered exosomes modified with antibodies (e.g., anti-HER2) or RGD peptides targeting αvβ3 integrins show significantly enhanced uptake by tumor cells both in vitro and in vivo, compared to unmodified controls [57].